Table 1. Clinical probability parameters of the Markov model.
| Parameter | Value | Range | Distribution | Source |
|---|---|---|---|---|
| CV mortality | ||||
| Empagliflozin group | 1.96 | 1.87–2.06 | Beta | EMPEROR-Reduced (8) |
| Control group | 2.12 | 2.02–2.23 | Beta | EMPEROR-Reduced (8) |
| With diabetes | ||||
| Empagliflozin group | 2.20 | 2.09–2.31 | Beta | EMPEROR-Reduced (8) |
| Control group | 2.41 | 2.29–2.53 | Beta | EMPEROR-Reduced (8) |
| Without diabetes | ||||
| Empagliflozin group | 1.73 | 1.64–1.82 | Beta | EMPEROR-Reduced (8) |
| Control group | 1.85 | 1.76–1.94 | Beta | EMPEROR-Reduced (8) |
| Non-CV mortality (age) | China CDC (12) | |||
| 65~ years | 0.24 | – | – | – |
| 70~ years | 0.31 | – | – | – |
| 75~ years | 0.45 | – | – | – |
| HF hospitalization | ||||
| Empagliflozin group | 2.62 | 2.49–2.75 | Beta | EMPEROR-Reduced (8) |
| Control group | 3.51 | 3.33–3.69 | Beta | EMPEROR-Reduced (8) |
| With diabetes | ||||
| Empagliflozin group | 3.02 | 2.87–3.17 | Beta | EMPEROR-Reduced (8) |
| Control group | 5.90 | 5.61–6.20 | Beta | EMPEROR-Reduced (8) |
| Without diabetes | ||||
| Empagliflozin group | 2.22 | 2.11–2.33 | Beta | EMPEROR-Reduced (8) |
| Control group | 3.00 | 2.85–3.15 | Beta | EMPEROR-Reduced (8) |
| HF readmission | 16.23 | 15.42–17.04 | Beta | Huang et al. (2) |
Values are percentages. All inputs are based on a 3-month cycle length. CDC, Center for Disease Control and Prevention; CV, cardiovascular; HF, heart failure.